Safety profile of Bilastine: 2nd generation h1-antihistamines

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 14, 2012, Pages 1999-2005

  Scaglione, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bilastine; H(1) antihistamine

Indexed keywords

ALCOHOL; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BILASTINE; CETIRIZINE; DESLORATADINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HYDROXYZINE; KETOCONAZOLE; LEVOCETIRIZINE; LORAZEPAM; PLACEBO;

ADULT DISEASE; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CHILDHOOD DISEASE; DIZZINESS; DRIVING ABILITY; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAM; FATIGUE; HAY FEVER; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERENNIAL RHINITIS; QT PROLONGATION; RHINOCONJUNCTIVITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; URTICARIA; VITAL SIGN;

ANIMALS; AUTOMOBILE DRIVING; BENZIMIDAZOLES; CONJUNCTIVITIS, ALLERGIC; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; PIPERIDINES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; URTICARIA; WAKEFULNESS;

EID: 84874080298     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. GANTZ I, SCHAFFER M, DELVALLE J., LOGSDON C, CAMPBELL V, UHLER M., YAMADA T. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci U S A 1991; 88: 429-433.
2. DE BACKER M.D., GOMMEREN W, MOEREELS H., NOBELS G, VAN GOMPEL P, LEYSEN JE, LUYTEN WH Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun 1993; 197: 1601-1608.
3. LOVENBERG TW, ROLAND BL, WILSON S.J., JIANG X., PYATI J, HUVAR A, JACKSON M.R., ERLANDER MG Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999; 55: 1101-1017.
4. ODA T, MORIKAWA N, SAITO Y., MASUHO Y, MATSUMOTO S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275: 36781-36786.
5. LEURS R, VISCHER H F, WIJTMANS M, DE ESCH IJP. En route to new blockbuster antihistamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci 2011; 32: 250-257.
6. Simons FER, Simons KJ Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128: 1139-1150.
7. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(5 Suppl. 1): s147-334.
8. WEDI B. Urticaria. J Dtsch Dermatol Ges 2008; 6: 306-317.
9. SIMONS FER. Advances in H1-antihistamines. N Engl J Med 2004; 351: 2203-2217.
10. NIJMEIJER S, LEURS R, VISCHER H F. Constitutive activity of the histamine H(1) receptor. Methods Enzymol 2010; 484: 127-147.
11. BAKKER RA, SCHOONUS SB, SMIT M.J., TIMMERMAN H., LEURS R. Histamine H1-receptor activation of nuclear factor-kB: roles for Gbg-and Gaq/11-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133-1142.
12. YANAI K, ZHANG D, TASHIRO M., YOSHIKAWA T, NAGANUMA F, HARADA R., NAKAMURA T, SHIBUYA K, OKAMURA N. Positron emission tomography evaluation of sedative properties of antihistamines. Expert Opin Drug Saf 2011; 10: 613-622.
13. ZHANG D, TASHIRO M, SHIBUYA K., OKAMURA N, FUNAKI Y, YOSHIKAWA T., KATO M, YANAL K. Next-day residual sedative effect after night time administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. J Clin Psychopharmacol 2010; 30: 694-701.
14. DEVILLIER P, ROCHE N, FAISY C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet 2008; 47: 217-230.
15. OBRADOVIC T, DOBSON GG, SHINGAKI T, KUNGU T., HIDALGO IJ Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 2007; 24: 318-327.
16. CHEN C, HANSON E, WATSON J.W., LEE JS P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003; 31: 312-318.
17. LIEBERMAN P. Histamine, antihistamines, and the central nervous system. Allergy Asthma Proc 2009; 30: 482-486.
18. CARTER NJ. Bilastine in allergic rhinitis and urticaria. Drugs 2012; 72: 1257-1269.
19. CHURCH MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011; 10: 779-793.
20. JAUREGIZAR N, DE LA FUENTE L, LUCERO ML, SOLOGUREN A, LEAL N, RODRIGUEZ M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009; 48: 543-554.
21. BOUSQUET J, ANSÓTEGUI I, CANONICA G.W., ZUBERBIER T., BAENA-CAGNANI CE, BACHERT C, CRUZ A.A., GONZÁLEZ SN, KUNA P., MORAIS-ALMEIDA M, MULLOL J, RYAN D P, SÁNCHEZ-BORGES M, VALIENTE R, CHURCH MK. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131-139.
22. Cumulative Nce introduction index, 1983-2010. Annual Reports in Medicinal Chemistry. Ann Rep Med Chem 2011; 46: 531.
23. CORCÓSTEGUI R., LABEAGA L, INNERÁRITY A, BERISA A., ORJALES A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6: 371-384.
24. CORCÓSTEGUI R., LABEAGA L, INNERÁRITY A, BERISA A., ORJALES A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006; 7: 219-231.
25. JAUREGIZAR N, DE LA FUENTE L, LUCERO ML, SOLOGUREN A, LEAL N, Rodríguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of Bilastine. Clin Pharmacokinet 2009; 48: 543-554.
26. CHURCH MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011; 10: 779-793.
27. CREAN CS, ROUPE KR, SOLOGUREN A, et al The pharmacokinetics of bilastine after single and 14 days once daily administration [abstract no. P252]. Basic Clin Pharmacol Toxicol 2007; 101(Suppl. 1): 148.
28. JÁUREGUI I., GARCÍA-LIRIO E, SORIANO, ANA M, GAMBOA PM, ANTÉPARA I. An overview of the novel H1-anti-histamine bilastine in allergic rhinitis and urticaria. Expert Review of Clinical Immunology 2012; 8: 33-41.
29. LUCERO ML, GONZALO A, MUMFORD R., BETANZOS M, ALEJANDRO A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol 2012; 35(SUPPL. 1): 18-24.
30. JAUREGIZAR N, DE LA FUENTE L, LUCERO ML, SOLOGUREN A, LEAL N, Rodríguez M. Pharmacokinetic-Pharmacodynamic Modelling of the Antihistaminic (H1) Effect of Bilastine. Clin Pharmacokinet 2009; 48: 543-554.
31. SOLOGUREN A, LUCERO ML, VALIENTE R, et al Human mass balance with [14C]-bilastine following oral administration to healthy volunteers [abstract no. TP85]. Basic Clin Pharmacol Toxicol 2009; 105(Suppl. 1): 106-107.
32. BILASTINE (F-96221-BMI). A novel antihistamine compound for the treatment of allergic rhinitis and chronic idiopathic ur ticaria. Available at http://www.faes.es (Accessed June 2012).
33. HORAK F, ZIEGLMAYER P, ZIEGLMAYER R., LEMELL P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010; 59: 391-398.
34. SASTRE J, MULLOL J, VALERO A., VALIENTE R; BILASTINE STUDY GROUP. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121-130.
35. KUNA P, BACHERT C, NOWACKI Z., VAN CAUWENBERGE P, AGACHE I, FOUQUERT L., ROGER A, SOLOGUREN A, VALIENTE R; BILASTINE INTERNATIONAL WORKING GROUP. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39: 1338-1347.
36. BACHERT C, KUNA P, SANQUER F., I VAN P, DIMITROV V, GORINA M.M., VAN DE HEYNING P, LOUREIRO A; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64: 158-165.
37. ZUBERBIER T, OANTA A, BOGACKA E., MEDINA I, WESEL F, UHL P., ANTÉPARA I, JÁUREGUI I, VALIENTE R; BILASTINE INTERNATIONAL WORKING GROUP. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5mg for the treatment of chronic idiopathic urticaria: a multicentre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65: 516-528.
38. MONTORO J, DEL CUVILLO A, JÀUREGUI I, et al Bilastine and the central nervous system: incidence of somnolence [abstract no. 926]. Allergy 2011; 66(Suppl. 94): 358.
39. GARCÍA-GEA C., MARTÍNEZ-COLOMER J, ANTONIJOAN RM, VALIENTE R, BARBANOJ MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008; 28: 675-685.
40. GARCÍA-GEA C., CLOS S, ANTINIJOAN R.M., GICH I., VALIENTE R, BARBANOJ MJ Crossover, randomised, doubleblind, double-dummy, placebo and positive standard-controlled trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0'8 g/kg) after single simultaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol 2006; 99(Suppl. 1): 30.
41. BACHERT C, KUNA P, ZUBERBIER T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010; 65(SUPPL. 93): 1-13.
42. CONEN S, THEUNISSEN EL, VAN OERS AC, VALIENTE R, RAMAEKERS JG Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2010; 25: 1517-1523.
43. GRAFF C, STRUIJK JJ, KANTERS J.K., ANDERSEN M P, TOFT E, TYL B. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, doubleblind, placebo-controlled, thorough QTc study. Clin Drug Invest 2012; 32: 339-351.
44. TYL B, KABBAJ M, AZZAM S., SOLOGUREN A, VALIENTE R, REINBOLT E., ROUPE K, BLANCO N, WHEELER W. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52: 893-903.
45. MUMFORD R, ALLAN L, HOEY R., PATTERSON A, ORJALES A, LUCERO M.L., CREAN C. The disposition, metabolism and elimination in rats of bilastine, a potent, selective H1 receptor antagonist. Drug Metab Rev 2007; 39(Suppl I): 200-201.